Biogen Idec Inc 

BIIB:NASDAQ

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
291.72 6.23   2.18%0.00%955,4732.4M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

As of 12:54 PM ET 4/16/2014

Latest News Headlines for Biogen Idec Inc

Biogen Idec to Present New Clinical Data from Its -2-

TYSABRI has advanced the treatment of MS patients with its established efficacy. Data from the Phase 3 AFFIRM trial, which was published in the New England Journal of Medicine, showed that after two years, TYSABRI treatment led to a 68 percent relative reduction (p<0.001) in the annualized relapse rate when compared with placebo and reduced the relative risk of disability progression by 42-54 percent (p<0.001).

Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting

- Two-Year Data from Pivotal Phase 3 ADVANCE Study for PLEGRIDY(TM) (Peginterferon Beta-1a) to Be Presented - - New TECFIDERA(R) (dimethyl fumarate) Data Underscore Efficacy, Consistent with Growing Global Experience with Greater than 65,000 Patients Treated Worldwide(1) -

Biogen Idec Names Adam M. Koppel as SVP and Chief Strategy Officer

-- Will Lead Corporate Strategy and Portfolio Management in Newly Created Role -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 10, 2014-- Biogen Idec (NASDAQ: BIIB) today announced the appointment of Adam M. Koppel, M.D., Ph.D., as senior vice president and chief strategy officer, effective May 15, 2014.

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company's products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

http://www.biogenidec.com/

Loading...
Bid/SizeAsk/Size
-- / ---- / --
Price OpenPrevious Close
290.28285.49
Day HighDay Low
294.00284.07
52wk High/Date52wk Low/Date
358.89 / 3/19/2014194.66 / 6/21/2013
% off 52wk High% off 52wk Low
(18.72)%49.86%
Beta (5 Yr)Market Capitalization
1.269.0B Large Cap
Shares OutstandingVolatility Avg
236.4M38.33
EPS(TTM)P/E Ratio
7.8237.3
Dividend AnnouncementDividend Yield
--0.00%
Ex-DateDate of Record
----
PayablePayable Date
0.00 - ----

Last Trade as of 4/16/2014 12:52 PM ET

Peers Information HelpBIIB Biogen Idec Inc vs. Peers

Peers 
BIIB
Biogen Idec Inc
2.12%
Johnson & Johnson
8.31%
Pfizer Inc.
-2.42%
Merck & Co., Inc.
11.99%
BIIB
Biogen Idec Inc
0.00%
Johnson & Johnson
2.66%
Pfizer Inc.
3.48%
Merck & Co., Inc.
3.14%
BIIB
Biogen Idec Inc
2.18%
Johnson & Johnson
-0.42%
Pfizer Inc.
0.45%
Merck & Co., Inc.
0.37%
Compare these stocks